Lilly In Collaboration To Screen NIH Pharmaceuticals Collection, Make Pharmacology Data Public

Repurposing opportunities are unlikely in this NCATS/Lilly project, which has the loftier goal of furthering understanding of how small molecule drugs actually work in complex human systems in order to improve drug development for the entire “research universe.”

Lilly Research Laboratories will apply its Phenotypic Drug Discovery assays to 3,800 approved and investigational small molecule drugs from the National Institutes of Health’s collection of all known drugs approved for human use, with the goal of improving drug development by providing a better understanding of how drugs work in complex human systems. The project should take 12 to 18 months, and all data will be made public following the Human Genome Project model.

“If we’re going to get better at making drugs that do good things and don’t do bad things, then we...

More from R&D

More from Pink Sheet

New Drug Procurement Rules Aim To Drive Pharma Investment In Mexico

 

Legal experts warn, however, that new Mexican procurement rules are discriminatory and could be challenged in the courts.

EU CHMP Opinions And MAA Updates

 

This is an update of recommendations from the European Medicines Agency's Committee for Medicinal Products for Human Use on the authorization of new medicines in the EU, and updates on EU marketing authorization changes recommended by the CHMP.

Crosstalk On Drug Pricing: Conflicts In Trump Team Rhetoric And Policy

 

The Trump Administration’s rhetoric and policy approaches illustrate the confusion that often arises between efforts to cut drug prices and cutting spending.